ReviewCurrent nutrition reports2026
The Potential Neuroprotective Role of Biotin in Neurorehabilitation: A Review.
Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBiotin is a water-soluble vitamin that mammals cannot synthesize and must obtain from the diet. Beyond its established role as a cofactor for biotin-dependent carboxylases, biotin has attracted neurological interest because intermediary metabolism, lipid handling, and myelin maintenance are biologically linked. This narrative review examines biotin across three distinct exposure contexts-nutritional adequacy, functional insufficiency, and pharmacological supplementation-and evaluates its putative relevance to neuroprotection and neurorecovery-oriented processes. RECENT
findingsDietary biotin intake is generally sufficient in mixed diets, and overt deficiency is uncommon; however, low diet quality, reduced bioavailability, and methodological limitations in status assessment may complicate interpretation of biotin sufficiency in clinical nutrition. No validated gold-standard biomarker is currently available. Experimental studies suggest that biotin may modulate pathways related to cellular bioenergetics, lipid metabolism, and myelin-associated processes, but these findings are predominantly preclinical and should not be interpreted as direct evidence of clinical efficacy. In progressive multiple sclerosis, high-dose biotin has been evaluated in human studies, including randomized trials, yet clinical results remain inconsistent and laboratory assay interference remains a relevant practical limitation. Current evidence does not support conflating adequate dietary biotin intake with pharmacological high-dose exposure. Although biotin remains mechanistically plausible in neuroenergetics and myelin-related disorders, its therapeutic relevance to neurorecovery remains uncertain. Better-designed studies are needed to refine exposure assessment, define dose-response relationships, and determine whether mechanistic signals translate into meaningful clinical benefit.
Indexed as
Identifiers
42734725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.